Pancreatic Cancer Adjuvant Therapy: ASCO Tumor Boards

This is a case-based activity that includes discussion of a 65-year-old male, with no chronic medical problems but had a 40-pack year history of cigarette smoking.  He presented with painless jaundice. In the past three months he has lost 20 pounds. His father, who was also a smoker, died from pancreatic cancer at the age of 73.

Learning Objectives

  • Describe the criteria for resectability for pancreatic adenocarcinoma
  • Describe the evolution of adjuvant therapy clinical trials over the last three decades
  • Acknowledge the different practice patterns regarding the utilization of adjuvant radiation therapy
  • Review the data supporting the use of capecitabine and gemcitabine in the adjuvant treatment of ductal adenocarcinoma of the pancreas from the ESPAC-4 trial
  • Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on January 18, 2019. Participants must complete all necessary course components by this date to receive credit.
  • This course is available as part of the 2017 ASCO Tumor Boards bundle.